Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil
批准号:
9276610
负责人:
JONATHAN E. GOLUB
金额:
$56.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-06-25 至 2019-05-31
关键词:
AIDS/HIV problemAdherenceBiological AssayBloodBlood TestsBrazilCaringCause of DeathClinicCluster randomized trialCollectionConceptionsConsensusDeveloping CountriesDiagnosisDiagnosticDiagnostic testsDimensionsDiseaseEligibility DeterminationEnsureEpidemicEvaluationGoalsGoldGuidelinesHIVHealth Knowledge, Attitudes, PracticeHuman ResourcesIncidenceInfectionInterferon Type IIInterventionLatin AmericaLinkMonitorOutcomeOutcome StudyPatient riskPatientsPerformancePersonsPopulationPreventive therapyProceduresProcessProviderPublishingQuality-Adjusted Life YearsRiskServicesStructureTestingTimeTubeTuberculin TestTuberculosisViral load measurementWorkWorld Health Organizationarmbaseclinical carecost effectivecost effectivenessexperiencehigh riskhigh risk populationimprovedinnovationisoniazidlatent infectionnew technologyperformance testspreventprogramspublic health relevancescreeningstandard of careuptakevaccination against tuberculosis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Tuberculosis (TB) is the most common cause of death among people living with HIV. Diagnosing latent tuberculosis infection (LTBI) among HIV-infected patients is challenging, as the most commonly used test, the tuberculin skin test (TST), is out-dated, has poor sensitivity in HIV-infected and BCG vaccinated populations, and is operationally difficult to administer. The World Health Organization currently recommends that in regions where the TST can be implemented to detect LTBI, provision of preventive therapy is recommended only for HIV-infected patients with a positive TST. A new blood assay, Quantiferon TB Gold In-Tube (QGIT) test, has been recently approved by the US FDA for detecting LTBI, however relatively few published studies have evaluated this assay in HIV-infected patients and little information exists about the routine use of QGIT, i.e. test performance under routine clinical care conditions and optimal operationalization of this blood test. We propose a cluster randomized trial (CRT) to compare QGIT performance in HIV-infected persons attending public HIV clinics in Rio de Janeiro, Brazil with routine TST, and to determine if QGIT more quickly identifies HIV-infected patients who are latently infected and leads to faster initiation of TB preventive therapy. We will link QGIT testing with routine CD4 monitoring which will eliminate the burden of the routine clinic staff and minimally interfere with routine blood draws. Delays in TST and provision of isoniazid preventive therapy in Rio de Janeiro are extremely long, and risk of TB disease is quite high among HIV-infected patients waiting for a TST, thus a better strategy is needed. The specific aims of the study are 1) to compare the impact of linking QGIT with CD4 blood collection and the current standard of care process of TST in HIV clinics in Rio de Janeiro, Brazil on operational metrics, 2) to compare cost-effectiveness of implementing QGIT versus standard practice of TST, and 3) to explore attitudinal and operational factors influencing successful implementation of QGIT. Our primary focus on linking QGIT with routine CD4 blood draws is innovative and logical given the parameters of the test. These findings, in addition to conducting a structured process evaluation of the implementation of the intervention and determining the cost effectiveness of QGIT compared to TST will provide the best evidence to date comparing these two tests in an operational setting in a developing country, and guide dissemination and implementation of this strategy throughout Brazil and other regions where TST is ineffective at diagnosing latent infection in HIV- infected patients.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa.
南非艾滋病毒感染孕妇普遍使用异烟肼预防性治疗的成本效益。
DOI:
10.5588/ijtld.18.0370
发表时间:
2018
期刊:
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
影响因子:
--
作者:
[Kim,H-Y, Hanrahan,CF, Martinson,N, Golub,JE, Dowdy,DW]
通讯作者:
Dowdy,DW
DOI:
10.1007/s10461-018-2324-x
发表时间:
2019-07
期刊:
AIDS and behavior
影响因子:
4.4
作者:
[Kim HY, Dowdy DW, Martinson NA, Kerrigan D, Tudor C, Golub J, Bridges JFP, Hanrahan CF]
通讯作者:
Hanrahan CF
DOI:
10.5588/ijtld.18.0740
发表时间:
2020-04-01
期刊:
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
影响因子:
--
作者:
[Kim HY, Hanrahan CF, Dowdy DW, Martinson NA, Golub JE, Bridges JFP]
通讯作者:
Bridges JFP
TB PuRe : Pulmonary rehabilitation to reduce post-tuberculosis morbidity
-
批准号:10586385
-
项目类别:
-
资助金额:$68.24万
-
财政年份:2023
-
负责人:JONATHAN E. GOLUB
-
依托单位:
Developmental Core
-
批准号:10431022
-
项目类别:
-
资助金额:$28.51万
-
财政年份:2022
-
负责人:JONATHAN E. GOLUB
-
依托单位:
Developmental Core
-
批准号:10593147
-
项目类别:
-
资助金额:$28.78万
-
财政年份:2022
-
负责人:JONATHAN E. GOLUB
-
依托单位:
Evaluating smoking cessation interventions for PWH in South Africa: Efficacy, implementation, and cost-effectiveness.
-
批准号:10269650
-
项目类别:
-
资助金额:$67.35万
-
财政年份:2021
-
负责人:JONATHAN E. GOLUB
-
依托单位:
TB Aftermath
-
批准号:9895147
-
项目类别:
-
资助金额:$69.55万
-
财政年份:2020
-
负责人:JONATHAN E. GOLUB
-
依托单位:
TB Aftermath
-
批准号:10431874
-
项目类别:
-
资助金额:$62.57万
-
财政年份:2020
-
负责人:JONATHAN E. GOLUB
-
依托单位:
TB Aftermath
-
批准号:10171763
-
项目类别:
-
资助金额:$63.2万
-
财政年份:2020
-
负责人:JONATHAN E. GOLUB
-
依托单位:
PREVINE-TB: PRevent: EValuating the implementation of NEw strategies for preventive TB among people living with HIV in Brazil
-
批准号:10179305
-
项目类别:
-
资助金额:$56.9万
-
财政年份:2018
-
负责人:JONATHAN E. GOLUB
-
依托单位:
PREVINE-TB: PRevent: EValuating the implementation of NEw strategies for preventive TB among people living with HIV in Brazil
-
批准号:10426171
-
项目类别:
-
资助金额:$57.19万
-
财政年份:2018
-
负责人:JONATHAN E. GOLUB
-
依托单位:
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil
-
批准号:8843075
-
项目类别:
-
资助金额:$33.94万
-
财政年份:2013
-
负责人:JONATHAN E. GOLUB
-
依托单位:
The Impact of Diabetes on TB treatment outcomes
-
批准号:8607116
-
项目类别:
-
资助金额:$59.21万
-
财政年份:2013
-
负责人:JONATHAN E. GOLUB
-
依托单位:
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil
-
批准号:9064738
-
项目类别:
-
资助金额:$76.57万
-
财政年份:2013
-
负责人:JONATHAN E. GOLUB
-
依托单位:
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil
-
批准号:8688888
-
项目类别:
-
资助金额:$57.21万
-
财政年份:2013
-
负责人:JONATHAN E. GOLUB
-
依托单位:
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil
-
批准号:8209846
-
项目类别:
-
资助金额:$60.04万
-
财政年份:2013
-
负责人:JONATHAN E. GOLUB
-
依托单位:
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil
-
批准号:8842578
-
项目类别:
-
资助金额:$56.78万
-
财政年份:2013
-
负责人:JONATHAN E. GOLUB
-
依托单位:
The Impact of Diabetes on TB treatment outcomes
-
批准号:8305333
-
项目类别:
-
资助金额:$59.18万
-
财政年份:2013
-
负责人:JONATHAN E. GOLUB
-
依托单位:
A Smoking Cessation Trial in HIV-infected patients in South Africa
-
批准号:8508235
-
项目类别:
-
资助金额:$51.79万
-
财政年份:2011
-
负责人:JONATHAN E. GOLUB
-
依托单位:
A Smoking Cessation Trial in HIV-infected patients in South Africa
-
批准号:8071823
-
项目类别:
-
资助金额:$51.27万
-
财政年份:2011
-
负责人:JONATHAN E. GOLUB
-
依托单位:
A Smoking Cessation Trial in HIV-infected patients in South Africa
-
批准号:8703649
-
项目类别:
-
资助金额:$48.7万
-
财政年份:2011
-
负责人:JONATHAN E. GOLUB
-
依托单位:
A Smoking Cessation Trial in HIV-infected patients in South Africa
-
批准号:8330818
-
项目类别:
-
资助金额:$52.92万
-
财政年份:2011
-
负责人:JONATHAN E. GOLUB
-
依托单位:
海外基金